Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Arcus Biosciences, Inc. ( RCUS ) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 12:20 PM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Robert Goeltz - Principal Financial Officer & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Morgan Stanley, Research Division All right. Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So I'm very pleased to be hosting this afternoon, Arcus. We have Terry Rosen, the company's CEO, and Bob Goeltz, the company's CFO. Thank you both so much for joining me. Really appreciate it. Question-and-Answer Session Terence Flynn Morgan Stanley, Research Division And I guess, again, maybe just high level to get started. How should we think about the company, Terry? There have been a lot of changes over the years. Is this really a single product story or is there a platform strategy here? I know a lot of focus on casdatifan, which we'll dig into, but how should we think more broadly about what the company is doing beyond cas? Terry Rosen Co-Founder, Chairman & CEO So first of all, thank you, Terence, for doing this, and thank you for all of those of you who are joining us. And I think very clearly, casdatifan obviously is a center of focus for us, for the world. We believe very strongly it's going to be $5 billion to $10 billion drug. So not surprisingly, that question will come up. But I think Arcus continues to be, as we plan since its inception, to be a company that's focused with a long-term vision. We have a very